Continuously Evolving Management Concepts for Diabetic CKD and ESRD

Seminars in Dialysis

Volumn 23, Issue 2, 2010, Pages 134-139

  Friedman, Eli A ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; HUMAN; KIDNEY TRANSPLANTATION; PANCREAS TRANSPLANTATION; PERITONEAL DIALYSIS; PROTEOMICS; UREMIA; DIABETIC NEPHROPATHIES; KIDNEY FAILURE, CHRONIC;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; DIABETIC NEPHROPATHIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PANCREAS TRANSPLANTATION; PERITONEAL DIALYSIS; PROTEOMICS; UREMIA; HYPOLIPIDEMIC AGENTS;

EID: 77953264687     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2009.00699.x     Document Type: Article

References (38)

1. USRDS 2008 Annual Data Report: Atlas of End-Stage Renal Disease in the United States 2008, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
2. World Health Organization, Fact sheet No 312. November 2008; WHO Media centre:
3. Atta MG, Baptiste-Roberts K, Brancati FL, Gary TL. The natural course of microalbuminuria among African Americans with Type 2 diabetes: a 3-year study. Am J Med 2009, 122:62-72.
4. Mogensen CE. Twelve shifting paradigms in diabetic renal disease and hypertension. Diabetes Res Clin Pract 2008, 82S:S2-S9.
5. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998, 339:115-117.
6. Barnett A. Prevention of loss of renal function over time in patients with diabetic nephropathy. Am J Med 2006, 119(5 Suppl 1):S40-S47.
7. Kalaitzidis R, Bakris G. Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy? Postgrad Med 2009, 121:77-88.
8. Parfrey PD. Angiotensin-receptor blockers in the prevention or treatment of microalbuminuria. Ann Intern Med 2009, 151:63-65.
9. Mauer M, Zinman B, Gardiner R, Suissas S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R. Renal and retinal effects of enalapril and losartan in Type 1 diabetes. N Engl J Med 2009, 361:40-51.
10. Abe H, Minatoguchi S, Ohashi H, Mauarale I, Minagawa T, Okuma T, Yokoyama H, Takatsu H, Takeya T, Naagano T, Osumi Y, Kakami M, Tsukamoto T, Tanaka T, Hiel K, Fujiwara H. Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in Type-2 diabetic patients with nephropathy. Hypertens Res 2007, 30:929-935.
11. Bakris GL. Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol 2008, 3(Suppl. 1):S3-S10.
12. Bakris GL, Weir MR. Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression. Postgrad Med 2008, 120:33-42.
13. Bode BW, Schwartz S, Stubbs HA, Block JE. Glycemic characteristics in continuously monitored patients with Type 1 and Type 2 diabetes: normative values. Diabetes Care 2005, 28:2361-2366.
14. Goals for blood glucose levels. Diabetes Care 2008, 31(Suppl. 1):S11.
15. Dijkstra RF, Niessen LW, Braspenning JC, Adang E, Grol RT. Patient-centred and professional-directed implementation strategies for diabetes guidelines: a cluster-randomized trial-based cost-effectiveness analysis. Diabetes Med 2006, 23:164-170.
16. McCarter RJ, Hempe JM, Chalew SA. Mean blood glucose and biological variation have greater influence on HbA1c levels than glucose instability: an analysis of data from the Diabetes Control and Complications Trial. Diabetes Care 2006, 29:352-355.
17. Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR. UKPDS 72 United Kingdom Prospective Diabetes Study. Cost-utility analyses of intensive blood glucose and tight blood pressure control in Type 2 diabetes (UKPDS 72). Diabetologia 2005, 48:868-877.
18. Effects of intensive glucose lowering in Type 2 diabetes. N Engl J Med 2008, 358:2545-2599.
19. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
20. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hébert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009, 360:1283-1297.
21. Harnden A, Lehman R. New primary care series: easily missed? BMJ 2009, 338:901-902.
22. Conway BR, Maxwell AP. Genetics of diabetic nephropathy: are there clues to the understanding of common kidney diseases? Nephron Clin Pract 2009, 112:c213-c221.
23. Njølstad PR, Molven A, Groop L. Diabetes genetics. A seventh sense for the successful sequel of 'come together'. " The genotypes and phenotypes of diabetes" Bergen, Norway. April 22-26, 2009. 2nd meeting of 'EASD Study Group on Genetics of Diabetes' and 44th annual meeting of the 'Scandinavian Society for the Study of Diabetes'. JOP 2009, 10:466-471.
24. Pozzilli P, Guglielmi C. Double diabetes: a mixture of Type 1 and Type 2 diabetes in youth. Endocr Dev 2009, 14:151-166.
25. Wirta O, Pasternack A, Laippala P, Turjanmaa V. Glomerular filtration rate and kidney size after six years disease duration in non-insulin-dependent diabetic subjects. Clin Nephrol 1996, 45:10-17.
26. Abourizk NN, Dunn JC. Types of diabetes according to National Diabetes Data Group Classification. Limited applicability and need to revisit. Diabetes Care 1990, 13:1120-1122.
27. Delano BG, Suresh U, Feldman J, Schneider D, Friedman EA. Dismal rehabilitation in predominantly Type II diabetics on dialysis in inner-city Brooklyn. Clin Nephrol 2000, 54:94-104.
28. Incidence of end-stage renal disease among persons with diabetes-United-States, 1990-2002. Morbidityand Mortality Weekly Report 2005, 54:1097-1100.
29. Miyata T, van Ypersele de Satrihou C. Renoprotection of angiotensin receptor blockers: beyond blood pressure lowering. Nephrol Dial Transplant 2006, 10:1-4.
30. Ghavamian M, Gutch CF, Kopp KF, Kolff WJ. The sad truth about hemodialysis in diabetic nephropathy. JAMA 1972, 222:1386-1389.
31. Delmonico FL, McBride MA. Analysis of the wait list and deaths among candidates waiting for a kidney transplant. Transplantation 2008, 86:1678-1683.
32. Thongboonkerd V. Searching for novel biomarkers and new therapeutic targets of diabetic nephropathy using proteomics approaches. Contrib Nephrol 2008, 160:37-52.
33. Rossing K, Mischak H, Dakna M, Zürbig P, Novak J, Julian BA, Good DM, Coon JJ, Tarnow L, Rossing P. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008, 19:1283-1290.
34. Thamer C, Machann J, Stefan N, Schäfer SA, Machicao F, Staiger H, Laakso M, Böttcher M, Claussen C, Schick F, Fritsche A, Haring HU. Variations in PPARD determine the change in body composition during lifestyle intervention: a whole-body magnetic resonance study. J Clin Endocrinol Metab 2008, 93:1497-1500.
35. Otu HH, Can H, Spentzos D, Nelson RG, Hanson RL, Looker HC, Knowler WC, Monroy M, Libermann TA, Karumanchi SA, Thadhani R. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 2007, 30:638-643.
36. Thrailkill KM, Nimmo T, Bunn RC, Cockrell GE, Moreau CS, Mackintosh S, Edmondson RD, Fowlkes JL. Microalbuminuria in Type 1 diabetes mellitus is associated with enhanced excretion of the endocytic, multiligand receptors megalin and cubilin. Diabetes Care 2009, 32:1266-1268.
37. Marcus AJ, Woodbury D. Fetal stem cells from extra-embryonic tissues: do not discard. J Cell Mol Med 2008, 12:730-742.
38. Wang T, Adcock J, Kuhtreiber W, Qiang D, Salleng KJ, Trenary I, Williams P. Successful allotransplantation of encapsulated islets in pancreatectomized canines for diabetic management without the use of immunosuppression. Transplantation 2008, 85:331-337.